5-amino-1mq clinical trials 5-Amino-1MQ Peptide - 50mg

AOD-9604 produced modest weight reductions in human trials, with the most notable 12-week Phase 2 study reporting approximately 2.6 kg average fat mass reduction at the 1 mg daily dose compared with 0.8 kg in placebo-treated participants

The study has several limitations, including potential bias in the self-reporting of vaccination status and the underreporting of previous COVID-19 infections

Rutsch, F., S

Any way, that is an overview of what is going on

At the biochemical level, this peptide acts as a ligand, binding to receptors to trigger intracellular cascades

It's worth noting that MIC B12 injections can be administered either intramuscularly (directly into the muscle) or subcutaneously (into the tissue layer between the skin and muscle)